As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > COMMENTARY
COMMENTARY
-
Generic Makers Baffled by New Govt Target, Quality and Supply Concerns Linger
June 15, 2015
-
Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
May 26, 2015
-
1 Year after Viagra Generic Debut, Freely Priced Generics Seem to Be Bringing Benefits
May 8, 2015
-
Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications
April 27, 2015
-
Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?
April 17, 2015
-
Patient Subsidy System Expanded for Intractable Diseases, What about Incentives for Drug Makers?
April 7, 2015
-
Abe Pledges Biosimilar Promotion, but Doctor Misconception and Lack of Incentives Remain as Challenges
March 30, 2015
-
SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted
March 17, 2015
-
Uncertainty Swirling around Possible Drug Price Cuts for 3 Straight Years
March 16, 2015
-
Drug Repositioning May Promise Greater Chance of Success, but Problems Remain
March 6, 2015
-
As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse
February 16, 2015
-
Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
February 2, 2015
-
Open Innovation Bandwagon Gathers Pace for Efficient Drug Discovery
January 26, 2015
-
Have AGs Finally Become a Good Option to Counter Generics?
January 19, 2015
-
Will Legal Regulation Propel or Stymie Clinical Research? “Risk-Based” Approach Holds Key
January 13, 2015
-
Can Pharmas and Wholesalers Work to Dispel “Negative Primary Margins on Sales”?
December 22, 2014
-
April-Sept. Earnings Signal Watershed in Japan’s Shift to Generics
December 15, 2014
-
Wonder Drug? Savior? Avigan Clinical Trial for Ebola May Not Provide Clear-Cut Answer
December 5, 2014
-
Torii Eager to Carve Out New Market with Japan’s 1st Sublingual Allergen Immunotherapy
November 25, 2014
-
Was Weak Yen a Plus for April-Sept. Earnings? Profits Partly Canceled Out by Higher R&D, Import Costs
November 18, 2014
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…